Who makes Solrikitug Low Dose?

Solrikitug Low Dose is developed by Uniquity One (UNI).

What development phase is Solrikitug Low Dose in?

Solrikitug Low Dose is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Solrikitug Low Dose

Uniquity One (UNI) · Phase 2 active Biologic

At a glance

Generic name	Solrikitug Low Dose
Sponsor	Uniquity One (UNI)
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate Solrikitug in Participants With COPD (ZION) (PHASE2)
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis (PHASE2)
A Study to Evaluate Solriktug in Adult Participants With Asthma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Solrikitug Low Dose CI brief — competitive landscape report
Solrikitug Low Dose updates RSS · CI watch RSS
Uniquity One (UNI) portfolio CI